White House Antibiotic Plan Takes Top-Down Approach To Boosting Research
This article was originally published in The Pink Sheet Daily
Executive Summary
Federal agencies, including the Defense Department, are instructed to create a biopharmaceutical incubator and get at least two new treatments into clinical trials by 2020.
You may also be interested in...
Antibiotic Spring? Regulatory Incentives Spur Activity – And Maybe Medical Advances
Regulatory incentives have been successful at attracting developers to antibiotic R&D, but significant medical advances have stubbornly remained rare. Now the pipeline has produced the first novel antibiotic to receive breakthrough status from US FDA and some Phase III trials are raising the efficacy bar to superiority.
Companies Reveal Hurdles In Providing Drugs Via Expanded Access Programs
GSK, Stealth BioTherapeutics and Blueprint Medicines discuss the difficulties getting participation of physicians, the excessive cost of expanded access, and whether physicians should report research data.
Current Pathways For Rare Disease Drugs Are Not Optimal, US FDA’s Califf Says
Anticipating a ‘tsunami of therapies’ for rare diseases, commissioner says the agency will have to think of creative approaches and employ regulatory flexibility for them. FDA considers copying the oncology center’s Project Facilitate for expanded access to other diseases.